NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity
K. Yamana, N. Suzuki, T. Ohtani, T. Machida, S. Ina (Omiya, Saitama, Japan)
Source: Annual Congress 2001 - New treatments for asthma and COPD: PDE4 inhibitors and anti-IGE
Disease area: Airway diseases
Rating:
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Yamana, N. Suzuki, T. Ohtani, T. Machida, S. Ina (Omiya, Saitama, Japan). NIK-616, a new type of selective phosphodiesteraseIV(PDE IV) inhibitor with reduced emetic activity. Eur Respir J 2001; 16: Suppl. 31, 335
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
Related content which might interest you:
NIK-616,a new type of selective PDE IV inhibitor with reduced emetic activity Source: Eur Respir J 2002; 20: Suppl. 38, 618s Year: 2002
Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, is effective in the treatment of asthma Source: Eur Respir J 2002; 20: Suppl. 38, 303s Year: 2002
Effects of a selective phosphodiesterase IV and V inhibitor in a murine model of chronic asthma Source: Eur Respir J 2004; 24: Suppl. 48, 128s Year: 2004
Dose-dependent inhibitory effect of Roflumilast, a new, orally active, selective phosphodiesterase 4 inhibitor, on allergen-induced early and late asthmatic reaction Source: Eur Respir J 2002; 20: Suppl. 38, 110s Year: 2002
A phase 2 multiple ascending dose study of the inhaled pan-JAK inhibitor nezulcitinib (TD-0903) in severe COVID-19 Source: Eur Respir J, 58 (4) 2100673; 10.1183/13993003.00673-2021 Year: 2021
The effect of an oral phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in primate asthma models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Molecular and cellular profile of the structurally novel phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004 Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
The phosphodiesterase 4 inhibitor SB 207499 selectively inhibits neutrophil functions Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The in vivo activity of AWD 12-353, a potent phosphodiesterase 4 (PDE) inhibitor for the treatment of allergic asthma and COPD Source: Eur Respir J 2003; 22: Suppl. 45, 107s Year: 2003
Roflumilast, a selective phosphodiesterase 4 inhibitor, shows efficacy and safety in the long-term treatment of asthma Source: Eur Respir J 2003; 22: Suppl. 45, 203s Year: 2003
A selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in guinea-pig antigen challenge and ferret emesis models Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
A potential new therapy for pulmonary hypertension with the use of compound 21, an angiotensin type 2 receptor (AT2R) agonist Source: Annual Congress 2012 - Pulmonary circulation: basic mechanisms, animal models and experimental treatments Year: 2012
A novel macrolide/fluoroketolide, solithromycin (CEM-101), reverses corticosteroid insensitivity via activation of protein phosphatase PP2A Source: Annual Congress 2011 - Phagocytes and dendritic cells Year: 2011
In vitro pharmacological characterization of CHF6001, a novel selective phosphodiesterase 4 (PDE4) inhibitor with a robust anti-inflammatory profile Source: International Congress 2014 – Novel targets and drugs for asthma and COPD Year: 2014
Efficacy of the selective phosphodiesterase (PDE) 4 inhibitor, BAY 19-8004, in a rat model of neutrophilic lung inflammation Source: Eur Respir J 2001; 18: Suppl. 33, 36s Year: 2001
Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects Source: Annual Congress 2003 - Novel drugs under development for the treatment of respiratory diseases Year: 2003
In vitro pharmacological characterization of the potent, lung selective pan-JAK inhibitor TD-8236 Source: International Congress 2019 – Advances in asthma pharmacology Year: 2019
The selective phosphodiesterase 4 inhibitor, cilomilast, inhibits interleukin-8-induced pulmonary neutrophil accumulation in the rabbit Source: Eur Respir J 2001; 18: Suppl. 33, 35s Year: 2001
The novel phosphodiesterase 4 inhibitor CI-1044 inhibits in vitro LPS-induced TNFα production in whole blood of COPD patients Source: Eur Respir J 2001; 18: Suppl. 33, 34s Year: 2001
The bronchodilatory and anti-inflammatory effect of MT-810, a novel selective phosphodiesterase-4 (PDE4) inhibitor Source: Eur Respir J 2006; 28: Suppl. 50, 434s Year: 2006